Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun Qu

Showing results (101-110 of 488) with videos related to

Pageof 49
Sort By:
Immunopharmacology and Immunotoxicology|June 25, 2019
Inhibitory effect of rapamycin on proliferation of human umbilical arterial smooth muscle cellsRui Jin, Wei Sun, Yan Bai, et al.
Frontiers in Oncology|November 29, 2023
Choline metabolism and its implications in cancerNan Yao, Wenqiang Li, Guoshuai Xu, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 24, 2026
Practical integration of ctDNA-defined minimal residual disease in gastrointestinal cancers: testing windows and evidence-aligned management frameworksNan Yao, Wenqiang Li, Ning Duan, et al.
Pharmacological Research|June 1, 2020
Corrigendum to "S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer" [Pharmacol Res. 155 (2020) 104717]Yu-Hang Zhang, Dong-Dong Luo, Sheng-Biao Wan, et al.
European Journal of Pharmacology|April 15, 2014
13F-1, a novel 5-fluorouracil prodrug containing an Asn-Gly-Arg (NO2) COOCH3 tripeptide, inhibits human colonic carcinoma growth by targeting Aminopeptidase N (APN/CD13)Shu-Xiang Cui, Hou-Li Zhang, Wen-Fang Xu, et al.
International Journal of Molecular Sciences|March 6, 2021
Potential Neuroprotective Mechanisms of Methamphetamine Treatment in Traumatic Brain Injury Defined by Large-Scale IonStar-Based Quantitative ProteomicsShichen Shen, Ming Zhang, Min Ma, et al.
Pharmacological Research|February 24, 2020
S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancerYu-Hang Zhang, Dong-Dong Luo, Sheng-Biao Wan, et al.
BMC Cancer|October 24, 2020
Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cellsJin Niu, Xue Wang, Jun Qu, et al.
Frontiers in Pharmacology|March 10, 2018
Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer CellsXu Zhu, Xiaomeng Shen, Jun Qu, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 8, 2018
Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer CellsXu Zhu, Xiaomeng Shen, Jun Qu, et al.
Pageof 49

Showing results (101-110 of 488) with videos related to

Sort By:
Pageof 49
Immunopharmacology and Immunotoxicology|June 25, 2019
Inhibitory effect of rapamycin on proliferation of human umbilical arterial smooth muscle cellsRui Jin, Wei Sun, Yan Bai, et al.
Frontiers in Oncology|November 29, 2023
Choline metabolism and its implications in cancerNan Yao, Wenqiang Li, Guoshuai Xu, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 24, 2026
Practical integration of ctDNA-defined minimal residual disease in gastrointestinal cancers: testing windows and evidence-aligned management frameworksNan Yao, Wenqiang Li, Ning Duan, et al.
Pharmacological Research|June 1, 2020
Corrigendum to "S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer" [Pharmacol Res. 155 (2020) 104717]Yu-Hang Zhang, Dong-Dong Luo, Sheng-Biao Wan, et al.
European Journal of Pharmacology|April 15, 2014
13F-1, a novel 5-fluorouracil prodrug containing an Asn-Gly-Arg (NO2) COOCH3 tripeptide, inhibits human colonic carcinoma growth by targeting Aminopeptidase N (APN/CD13)Shu-Xiang Cui, Hou-Li Zhang, Wen-Fang Xu, et al.
International Journal of Molecular Sciences|March 6, 2021
Potential Neuroprotective Mechanisms of Methamphetamine Treatment in Traumatic Brain Injury Defined by Large-Scale IonStar-Based Quantitative ProteomicsShichen Shen, Ming Zhang, Min Ma, et al.
Pharmacological Research|February 24, 2020
S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancerYu-Hang Zhang, Dong-Dong Luo, Sheng-Biao Wan, et al.
BMC Cancer|October 24, 2020
Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cellsJin Niu, Xue Wang, Jun Qu, et al.
Frontiers in Pharmacology|March 10, 2018
Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer CellsXu Zhu, Xiaomeng Shen, Jun Qu, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 8, 2018
Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer CellsXu Zhu, Xiaomeng Shen, Jun Qu, et al.
Pageof 49